Editorial Advisory Board Spotlight: Susan J. Schniepp
September 10th 2024Susan J. Schniepp, member of the editorial advisory boards for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International, provides an update on her experience working in the pharmaceutical industry and what she sees for the industry’s future.
Behind the Headlines: Weight Loss Drugs; Price Controls; and Free COVID Therapies
September 5th 2024This Behind the Headlines news roundup panel discussion covers news items such as the weight loss drugs battle between Novo Nordisk and Eli Lilly, entering new territory through Lilly’s partnership with HAYA Therapeutics and long non-coding sequence mining. There was much discussion on how the inflation reduction act and Medicare price controls may or may not pertain—given the uncertainty around the presidential election results, and subsequent policy directions. The Centers for Disease Control making cost free COVID-19 diagnostics and therapies available was also evaluated.
Drug Digest: Evaluating Aseptic Processing and Manufacturing
September 5th 2024In this episode of Drug Digest, discussion with industry experts will highlight the challenges impacting aseptic processing and manufacturing, the intricacies of the regulatory landscape, and the necessity of addressing QC/QA early on, among other critical aspects.
Submitting Regulatory Applications Connects to Quality
August 22nd 2024In this episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice president, Technical at Parexel, discuss submitting biologics license applications and working with suppliers.
AAPS PharmSci 360 2024: Developing Inhalation Drugs
August 21st 2024For a preview of what's to come at the AAPS PharmSci 360 show in October, Pharmaceutical Technology® spoke with Vivek Gupta, PhD, associate dean for Graduate Education and Research, associate professor, Pharmaceutical Sciences, St. John’s University, Queens, New York, about the formulation of inhalation dosage forms.
Behind the Headlines: Mpox Resurges; Eli Lilly Adds CGT Facilities; FDA Updates
August 21st 2024This Behind the Headlines news roundup panel discussion covers news items such as the resurgence of mpox in Africa, “medical tourism” in India, Eli Lilly’s new Boston CGT facilities, and contract development and manufacturing organization (CDMO) projected growth rates for the 2023–2029 period, and the reasons behind them.
Drug Digest: Delving into Biopharmaceutical Development and Manufacturing
August 1st 2024In this exclusive Drug Digest video interview, Felicity Thomas, Associate Editorial Director, Pharmaceutical Technology Group, interviews experts from Biosynth and the University of Maryland about biopharmaceutical drug development and manufacturing.
Quality Considerations for Using AI in Bio/Pharma
July 24th 2024In the second episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice-president, Technical, at Parexel, discuss the quality requirements needed when incorporating AI in bio/pharmaceutical development and manufacturing.
Quality Considerations in Changing Excipient Providers
June 26th 2024In the premiere episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice president, Technical at Parexel, discuss the challenges involved in changing an excipient supplier.
Considerations in Pharmaceutical Facility Design (CPHI North America 2024)
June 14th 2024John Bertagnolli, vice-president of Commercial Operations at Selkirk Pharma, discusses considerations when building and scaling up pharmaceutical facilities, including contamination control and aseptic processing challenges.
Impact of Biosecure Act on the Pharma Industry (BIO 2024)
June 5th 2024Pharmaceutical Technology® spoke with Parviz Shamlou, senior vice-president of Science and Technology, Abzena, about the impact of the Biosecure Act on the bio/pharmaceutical industry, as well as the progress of continuous manufacturing in biopharma.